TOKYO -- Swiss pharmaceutical company Novartis plans to start mass production of radiopharmaceuticals, a type of next-generation cancer treatment, in Japan in 2026, Nikkei has learned.
Pharmaceuticals
Novartis to mass produce next-generation cancer drugs in Japan
Swiss drugmaker plans to start making radiopharmaceuticals there in 2026
Novartis currently produces radiopharmaceuticals in Europe and the U.S. and exports them to Japan. (Novartis)
Read Next
Latest on Pharmaceuticals
